Please login to the form below

Not currently logged in

Lilly's Strattera patent upheld in US

The US court of appeals has upheld the validity of Eli Lilly & Company's patent for ADHD drug Strattera

The US court of appeals has upheld the validity of Eli Lilly & Company's patent for attention deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine).

The decision overturns a previous ruling by a judge that Lilly's patent on the medicine was invalid, potentially opening the market to generic competition.

However, the most recent decision upholds Lilly's method-of-use patent which provides protection for Strattera until May, 2017.

Companies looking to capitalise on the loss of patent with their own versions of atomoxetine included Sun Pharmaceutical, Novartis' Sandoz unit, Aurobindo Pharma and Glenmark Pharmaceuticals.

Robert A Armitage, senior vice president and general counsel for Lilly, commented on the appeal: "In overturning the prior district court ruling, we believe that the Court fairly applied long-standing patent law principles."

1st August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...